I agree with you. This exaltation of the managment team has to be proved with facts and numbers. It 'a fact that Mr.. James has signed a contract with Martha S that within a few months can not pay. It 'sa fact that so wrong accounts: either production costs or sales forecasts or the amount to be paid to MS. As has been enhanced in the past year sales increase of 7000% not referring to the fact that at that time the sales were those of a shop in the suburbs, we should admit that we need a total overhaul of the management of NRTI. Many products are new this is true, and the data of only one quarter tell little, if not the fact that with a gross margin of 24% sales should be at least 30 times to create a hope for a draw. Expect the data for the 2nd quarter. Now the biggest risk is that if the choices that have been made with MS are repeated with the CBD-based products can go with the butt on the ground between two years. Do not think that the world of cannabis is the prerogative of NRTIs and TRTC, there are dozens of companies that are moving. As a shareholder I would like to know in the figures, which are the steeps of sales to be achieved it has set NRTI before reinvesting.
I've already lost a lot of money on false promises, I'm sorry I do not trust and I warn. I hope to be wrong for you, but the $ 0.02 expected by me is getting closer.
One last thing, even aloe barbadensis and aloe arborescens, cure cancer, I'm sorry that these indications have appeared on cannabis. We're talking about a production of cannabis-based food supplements, or pharmaceuticals? in Europe it changes a lot, I do not know in America. But any drug product is sold only in pharmacies and in doctor's prescription, a product "made with ..." dietary supplement, it can be found in supermarkets and large distribution. Where is oriented NRTIs?
